Jardiance Cost in Nevada 2026: Prices, Insurance, Medicaid and Compounded Options

What Is Empagliflozin and Why Does It Cost So Much?

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubule, lowering blood glucose while also reducing renal sodium retention and intraglomerular pressure. The FDA approved Jardiance (the brand formulation manufactured by Boehringer Ingelheim and Eli Lilly) first in 2014 for type 2 diabetes, then expanded the label to heart failure with reduced ejection fraction in 2021 and heart failure with preserved ejection fraction in 2022, and chronic kidney disease in 2023. You can review the full prescribing information at the FDA accessdata portal.

The dual-branded structure of Jardiance, two large pharmaceutical companies sharing revenue, contributes to a list price that has not seen meaningful generic competition. No small-molecule generic empagliflozin had received FDA approval as of the 2026 publication date of this article, meaning the brand price remains the dominant reference point for retail buyers in Nevada.

The EMPA-REG OUTCOME trial (N=7,020, published in NEJM 2015) demonstrated that empagliflozin 10 mg or 25 mg daily reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% relative to placebo (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority) [1]. Cardiovascular death specifically fell by 38% (HR 0.62 to 95% CI 0.49 to 0.77, P<0.001) [1]. That cardiovascular mortality signal is a major reason cardiologists and endocrinologists favor prescribing Jardiance over older, cheaper diabetes agents, which in turn sustains demand and list price.

The EMPEROR-Reduced trial (N=3,730, NEJM 2020) then showed empagliflozin reduced the composite of heart failure hospitalization or cardiovascular death by 25% (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) in patients with heart failure with reduced ejection fraction [2]. The EMPEROR-Preserved trial (N=5,988, NEJM 2021) confirmed a 21% reduction in the same composite endpoint in patients with preserved ejection fraction (HR 0.79 to 95% CI 0.69 to 0.90, P<0.001) [3]. These landmark results broadened the prescribing base well beyond diabetes specialists, increasing total demand.

Jardiance Retail Cash Price in Nevada in 2026

The average cash-pay price at retail pharmacies across Nevada is approximately $680 per month for a 30-day supply. This applies whether you fill the prescription at a major chain such as CVS or Walgreens in Las Vegas, a regional independent pharmacy in Reno, or a mail-order service with Nevada licensure. Price variation between individual pharmacy locations is typically less than 5%, because the wholesale acquisition cost set by Boehringer Ingelheim and Lilly is uniform nationally.

That $680 figure covers both the 10 mg and 25 mg tablet strengths; the two doses are priced identically at most Nevada pharmacies, which mirrors the national pricing structure maintained by the manufacturers.

GoodRx and similar discount aggregator cards can reduce that price to roughly $580 to $620 at participating Nevada pharmacies. The discount is applied at the point of sale and cannot be combined with insurance. The FDA's guidance on prescription drug pricing transparency explains why list price and net price differ; the gap between the two is absorbed largely by pharmacy benefit managers rather than passed to cash-pay patients [4].

The 2024 American Diabetes Association Standards of Care recommend SGLT2 inhibitors as first- or second-line agents alongside metformin for patients with type 2 diabetes who also have atherosclerotic cardiovascular disease, heart failure, or diabetic kidney disease, regardless of baseline HbA1c [5]. Because that recommendation applies to a large share of Nevada's type 2 diabetes population (the CDC estimated Nevada's adult diabetes prevalence at 11.4% in its most recent Behavioral Risk Factor Surveillance System release), demand for empagliflozin in the state is substantial [6].

Nevada Medicaid Coverage for Jardiance

Nevada Medicaid does not cover Jardiance on its preferred drug list for most enrollees in 2026. The state's Medicaid program, administered through managed care organizations under the Division of Health Care Financing and Policy, places empagliflozin in a non-preferred or non-covered tier for standard type 2 diabetes management when metformin or sulfonylureas are available as alternatives.

Prior authorization pathways theoretically exist, but approvals for brand-name SGLT2 inhibitors are rare when no contraindication to covered alternatives is documented. Patients with a confirmed diagnosis of heart failure with reduced ejection fraction may have a stronger prior authorization case, because the 2022 AHA/ACC/HFSA Heart Failure Guideline gives SGLT2 inhibitors a Class I, Level of Evidence A recommendation for heart failure with reduced ejection fraction to reduce hospitalizations and cardiovascular mortality [7]. Citing that guideline in a prior authorization letter is advisable.

Nevada Medicaid enrollees seeking coverage should ask their prescribing clinician to document:

1. Confirmed heart failure with reduced ejection fraction (EF <40%) or CKD with urine albumin-to-creatinine ratio above 200 mg/g.
2. Failure of or contraindication to at least one covered alternative.
3. The specific cardiovascular mortality benefit quantified in EMPA-REG OUTCOME [1].

Even with this documentation, denial rates are high. The most practical fallback for Medicaid enrollees who cannot afford retail cash price is either the manufacturer patient assistance program or compounded empagliflozin (discussed below).

Compounded Empagliflozin in Nevada: What Is Legal and What Is Not

Compounded empagliflozin produced by a state-licensed 503A pharmacy is legal to prescribe and dispense in Nevada as of 2026. A 503A pharmacy compounds for individual patients on the basis of a valid patient-specific prescription, operates under state Board of Pharmacy oversight, and is not subject to the same FDA manufacturing standards as commercial drug manufacturers. Nevada's Board of Pharmacy maintains its own inspection schedule for licensed compounding pharmacies; you can verify licensure at the Nevada State Board of Pharmacy.

The legal picture changed in 2024 when FDA added semaglutide to its shortage list, which opened 503B outsourcing-facility compounding. Empagliflozin is not on the FDA drug shortage database as of mid-2025, which means 503B outsourcing facilities cannot legally compound it at scale [8]. However, 503A pharmacies compounding for individual prescriptions face no such restriction, because 503A compounding of a drug that is not on shortage is permissible provided the compounded preparation is not a copy of a commercially available product that is not on shortage. Clinicians and patients should review the most current FDA 503A compounding guidance before proceeding [8].

The clinical consideration is that compounded empagliflozin is not bioequivalence-tested against Jardiance. The active pharmaceutical ingredient (API) used by compounding pharmacies must meet USP standards, but the tablet or capsule formulation has not undergone the comparative dissolution and pharmacokinetic studies required for FDA-approved generics. The ADA's 2024 Standards of Care do not endorse compounded SGLT2 inhibitors as a preferred alternative and note that substitution should involve shared clinical decision-making [5].

The HealthRX clinical team uses the following three-criterion framework when evaluating whether a Nevada patient is a reasonable candidate for compounded empagliflozin rather than brand Jardiance:

1. The patient is uninsured or has confirmed Medicaid non-coverage and cannot access the manufacturer savings card.
2. The prescribing clinician documents the therapeutic rationale and discloses the absence of bioequivalence data in the medical record.
3. The compounding pharmacy holds active Nevada Board of Pharmacy licensure and sources API from an FDA-registered supplier.

Insurance Coverage for Jardiance in Nevada

Most commercial insurance plans operating in Nevada include Jardiance on their formulary, typically at Tier 3 (preferred brand) or Tier 4 (non-preferred brand), resulting in copays of $50 to $150 per month after the deductible is met. Exchange plans sold through Nevada Health Link (the state's ACA marketplace) vary by insurer; several Silver-tier plans place empagliflozin on a Tier 3 specialty tier with copay assistance available.

Employer-sponsored plans managed by large PBMs (Express Scripts, CVS Caremark, OptumRx) generally place Jardiance on Tier 3 with a negotiated net cost to the plan substantially below the $680 list price. The patient's share depends on their specific plan design. The FDA's 2023 prescription drug pricing report notes that the average rebate percentage for branded diabetes medications in commercial channels was above 40% of list price [4].

Medicare Part D coverage in Nevada follows national formulary standards. Most Part D plans cover empagliflozin at Tier 3 or Tier 4. For 2026, the Medicare Prescription Payment Plan (the "smoothing" provision from the Inflation Reduction Act) caps out-of-pocket drug costs at $2,000 per year for Part D enrollees. For a patient paying $150/month on Jardiance, the annual cap provides meaningful protection once out-of-pocket costs accumulate past that threshold. CMS published the final IRA out-of-pocket cap details in the 2026 Part D Final Rule, and the American Heart Association's advocacy brief covers patient-level implications [9].

Boehringer Ingelheim and Lilly Savings Card

The Jardiance Savings Card, offered jointly by Boehringer Ingelheim and Eli Lilly, allows eligible commercially insured patients to pay as little as $10 per month for a 30-day or 90-day supply. The card functions as a secondary payer: it covers the difference between what insurance pays and the patient's out-of-pocket copay, up to a defined annual maximum (typically $1,800 to $3,600 per year).

Key eligibility restrictions apply. Patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government health program are not eligible. This exclusion covers a large share of Nevada's lower-income population. Uninsured patients are also generally ineligible for the standard savings card but may qualify for the Lilly Insulin Value Program analog or the Boehringer Ingelheim Cares Foundation patient assistance program, which can provide Jardiance at no cost to qualifying uninsured patients with household income below 400% of the federal poverty level.

The National Comprehensive Cancer Network's pharmacy guidance on manufacturer coupons (published in JNCCN, 2021) offers a broader discussion of how manufacturer savings programs interact with insurance cost-sharing structures, a dynamic directly relevant to Jardiance users [10].

To activate the savings card in Nevada, the patient presents the card (digital or physical) at any participating Nevada retail pharmacy at the time of pickup. Most major chains participate. The savings card cannot be applied to mail-order fills through certain PBMs, so patients should confirm eligibility with their specific pharmacy before filling a 90-day supply.

Telehealth Prescribing of Jardiance in Nevada

Nevada law permits telehealth prescribing of empagliflozin for established patients as well as, in most cases, new patients seen for the first time via synchronous audio-video visits. The Nevada Telehealth Act (NRS Chapter 629B) was updated in 2023 to maintain post-pandemic telehealth flexibilities for non-controlled substances. Empagliflozin is not a controlled substance, so no in-person visit requirement applies under state law.

Clinicians prescribing via telehealth must still conduct a clinically sufficient evaluation, which for empagliflozin includes review of kidney function (eGFR), current medications for drug interactions (notably diuretics, insulin, and sulfonylureas), genital mycotic infection history, and blood pressure. The FDA label for Jardiance contraindicates use when eGFR is below 20 mL/min/1.73 m² for the glucose-lowering indication, though the heart failure and CKD indications permit use at lower eGFR values [11].

The CREDENCE trial (N=4,401, NEJM 2019), conducted with canagliflozin rather than empagliflozin but directly informative for class-level telehealth evaluation, showed that SGLT2 inhibitors reduce the composite renal endpoint by 30% (HR 0.70 to 95% CI 0.59 to 0.82, P<0.001) in patients with diabetic kidney disease, which underscores why baseline renal assessment before prescribing is essential even in a telehealth context [12]. For empagliflozin specifically, the EMPA-KIDNEY trial (N=6,609, NEJM 2023) confirmed a 28% reduction in the composite of kidney disease progression or cardiovascular death (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) [13].

A telehealth clinician in Nevada should order a basic metabolic panel and urine albumin-to-creatinine ratio before or at the time of the initial Jardiance prescription if these values are not available from recent records (within 3 months).

Practical Cost-Reduction Pathways: A Step-by-Step Decision Map for Nevada Patients

The following sequence reflects the HealthRX clinical team's standard approach for Nevada-based patients who face barriers to affording Jardiance.

Step 1. Confirm insurance tier and deductible status. Many patients assume Jardiance is unaffordable before checking whether their plan's deductible has been met. Post-deductible Tier 3 copays at many Nevada commercial plans run $60 to $90 per month, which is substantially below the $680 list price.

Step 2. Apply the manufacturer savings card if commercially insured. The card can reduce copay to $10/month. Activation is free and takes under five minutes online at the Jardiance website.

Step 3. Request prior authorization for Medicaid if heart failure or CKD indication applies. Provide the EMPA-REG OUTCOME HR for cardiovascular death [1], the EMPEROR-Reduced composite endpoint result [2], and the AHA/ACC/HFSA 2022 Heart Failure Guideline Class I recommendation [7].

Step 4. Apply for Boehringer Ingelheim Cares Foundation patient assistance if uninsured and income-eligible. Processing takes 2 to 4 weeks. A 30-day bridge supply may be available while the application is reviewed.

Step 5. Consider compounded empagliflozin from a Nevada-licensed 503A pharmacy only if steps 1 through 4 are exhausted or not applicable. Ensure the pharmacy is Board-licensed and sources USP-grade API. Disclose to the patient that bioequivalence data are not available [8].

The 2024 AACE Comprehensive Diabetes Management Algorithm explicitly addresses cost as a factor in SGLT2 inhibitor selection, stating: "Medication cost and access are patient-centered factors that must be integrated into the shared decision-making process when selecting glucose-lowering agents." [14]

Safety Monitoring Nevada Clinicians Should Confirm Before Prescribing

Empagliflozin carries a class-level FDA boxed warning for lower-limb amputation risk (specifically noted for canagliflozin in the CANVAS trial, but the FDA extended a label warning class-wide). The FDA drug safety communication on SGLT2 inhibitors and amputation is the primary regulatory reference [15]. Peripheral artery disease, prior amputation, and active foot ulcers are relative contraindications that should be assessed at every prescribing encounter, including telehealth visits.

The FDA also issued a safety communication on Fournier's gangrene (necrotizing fasciitis of the perineum) associated with SGLT2 inhibitor use across the drug class [16]. Patients should be counseled to seek immediate care for perineal pain, swelling, or fever.

Diabetic ketoacidosis with near-normal blood glucose (euglycemic DKA) is a known risk, particularly in patients who are fasting, undergoing surgery, or on very-low-carbohydrate diets. The ADA's consensus statement on DKA and SGLT2 inhibitors recommends holding empagliflozin at least 3 days before elective surgery and educating patients to check urine or blood ketones whenever they feel unwell [17].

Genital mycotic infections are the most common adverse effect, occurring in approximately 6% to 9% of women and 3% to 4% of men in clinical trials, compared with 2% to 3% placebo rates. The EMPA-REG OUTCOME safety data capture this in the full trial population [1]. Most events are mild and respond to standard antifungal therapy.

Volume depletion and associated hypotension may occur, especially in older patients or those on loop diuretics. Checking baseline blood pressure and reviewing diuretic doses before starting empagliflozin is a standard precaution captured in the FDA prescribing label [11].